CLEARONE INC (CLRO): Nasdaq/NYSE listing notice — ClearOne gets 180-day Nasdaq extension to June 16, 2025 to regain $1.00 minimum bid price compliance

CLEARONE INC

Nasdaq granted ClearOne 180-day extension to June 16, 2025 to meet minimum $1.00 closing bid price requirement.
Company's stock previously non-compliant since June 2024; closing bid below $1.00 for 30 consecutive business days.
If compliance not regained by June 16, 2025, Nasdaq will issue delisting notice; company can appeal.
ClearOne may implement reverse stock split (subject to stockholder approval) to regain compliance.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

CLEARONE INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

ket (“Nasdaq”) notifying the Company that, because the closing bid price for its common stock had been below $1.00 per share for 30 consecutive business days, it is no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed companies to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until December 17, 2024, to regain compliance with the Minimum Bid Requirement. On Dece

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CLEARONE INC filing history →

Source: SEC EDGAR

accession 0001753926-24-002137

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.